Oligonucleotides for Inducing Paternal UBE3A Expression - Angelman Syndrome Treatment
Summary
USPTO granted patent US12596118B2 to Hoffmann-La Roche Inc. covering oligonucleotides capable of inducing expression of ubiquitin-protein ligase E3A (UBE3A) from the paternal allele for treatment of Angelman syndrome. The 30 claims target the suppressor of the UBE3A paternal allele via hybridization to SNHG14 long non-coding RNA downstream of SNORD109B.
What changed
USPTO issued patent grant US12596118B2 to Hoffmann-La Roche Inc., granting exclusive rights to oligonucleotides that induce paternal UBE3A expression for Angelman syndrome treatment. The patent covers compositions and methods using oligonucleotides targeting SNHG14 long non-coding RNA.
For pharmaceutical and biotechnology companies developing Angelman syndrome therapies, this patent establishes proprietary intellectual property that may affect freedom-to-operate for competing oligonucleotide-based treatments targeting UBE3A expression. Companies in this space should conduct patent clearance analyses.
What to do next
- Monitor patent portfolio for freedom-to-operate implications
- Review licensing opportunities for oligonucleotide-based Angelman syndrome treatments
Archived snapshot
Apr 16, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Oligonucleotides for inducing paternal UBE3A expression
Grant US12596118B2 Kind: B2 Apr 07, 2026
Assignee
Hoffmann-La Roche Inc.
Inventors
Veronica Costa, Maj Hedtjärn, Marius Hoener, Ravi Jagasia, Mads Aaboe Jensen, Christoph Patsch, Lykke Pedersen, Søren Vestergaard Rasmussen
Abstract
The present invention relates to oligonucleotides that are capable of inducing expression of ubiquitin-protein ligase E3A (UBE3A) from the paternal allele in animal or human neurons. The oligonucleotides target the suppressor of the UBE3A paternal allele by hybridization to SNHG14 long non-coding RNA downstream of SNORD109B. The present invention further relates to pharmaceutical compositions and methods for treatment of Angelman syndrome.
CPC Classifications
C12N 15/11 C12N 15/111 C12N 15/113 C12N 15/1137 C12N 2310/11 C12N 2310/315 C12N 2310/321 C12N 2310/322 C12N 2310/3231 C12N 2310/3341 C12N 2310/341 C12N 2310/346 A61K 31/7088
Filing Date
2025-07-02
Application No.
19258035
Claims
30
Related changes
Get daily alerts for USPTO Patent Grants - Biotech (C12N)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Biotech (C12N) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.